M. Mitten

发表

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

S. Korsmeyer, A. Letai, P. Hajduk, 2005, Nature.

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

C. Tse, S. Fesik, Eric F. Johnson, 2008, Cancer research.

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

L. Lam, C. Tse, Cheol‐Min Park, 2013, Nature Medicine.

Navitoclax (ABT‐263) and bendamustine ± rituximab induce enhanced killing of non‐Hodgkin's lymphoma tumours in vivo

J. Leverson, M. Mitten, E. Boghaert, 2012, British journal of pharmacology.

Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208

L. Lam, C. Tse, Cheol‐Min Park, 2013 .

Preclinical Development The Bcl-2 / Bcl-XL / Bcl-w Inhibitor , Navitoclax , Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo

C. Tse, H. Maecker, S. Rosenberg, 2011 .

Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors

L. Lam, T. Uziel, D. Albert, 2017, Molecular Cancer Therapeutics.

Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo

M. Mitten, J. Alder, K. Jarvis, 1993, Antimicrobial Agents and Chemotherapy.

Dynamics of Clarithromycin and Azithromycin Efficacies against Experimental Haemophilus influenzaePulmonary Infection

M. Mitten, J. Alder, A. Tovcimak, 1998, Antimicrobial Agents and Chemotherapy.

Synthesis and antibacterial activity of 6-O-arylpropargyl-9-oxime-11,12-carbamate ketolides.

M. Mitten, X. Beebe, S. Djurić, 2004, Bioorganic & medicinal chemistry letters.

In Vivo Efficacy of ABT-255 against Drug-Sensitive and -Resistant Mycobacterium tuberculosisStrains

M. Mitten, J. Alder, A. Tovcimak, 1998, Antimicrobial Agents and Chemotherapy.

Efficacies of ABT-773, a New Ketolide, against Experimental Bacterial Infections

M. Mitten, R. Flamm, J. Alder, 2001, Antimicrobial Agents and Chemotherapy.

Efficacy of A-73209, a potent orally active agent against VZV and HSV infections.

D. Norbeck, M. Mitten, E. Kern, 1994, Antiviral research.

Discovery of a series of cyclohexylethylamine-containing protein farnesyltransferase inhibitors exhibiting potent cellular activity.

S. Ng, S. Rosenberg, H. Sham, 1999, Journal of medicinal chemistry.

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Dolores Diaz, Jun Chen, Deepak Sampath, 2015, Science Translational Medicine.

Efficacies of ABT-719 and related 2-pyridones, members of a new class of antibacterial agents, against experimental bacterial infections

M. Mitten, N. Shipkowitz, J. Clement, 1995, Antimicrobial agents and chemotherapy.

Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.

Mary K Joseph, Saul H Rosenberg, Xiaohong Song, 2007, Journal of medicinal chemistry.

Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo

Yan Shi, V. Stoll, Eric F. Johnson, 2005, Molecular Cancer Therapeutics.

Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens.

M. Mitten, R. Clark, S. Wang, 2000, Journal of medicinal chemistry.

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

M. Amiot, F. Peale, Leslie B. Lee, 2016, Molecular Cancer Therapeutics.

Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate

Kedar S Vaidya, A. Scott, Mark G. Anderson, 2020, Molecular Cancer Therapeutics.

Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate

Kedar S Vaidya, A. Scott, A. Phillips, 2018, Molecular Cancer Therapeutics.

ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope

Kedar S Vaidya, A. Phillips, Dong Cheng, 2016, Molecular Cancer Therapeutics.

Inhibitor , Navitoclax , Enhances the Activity of Chemotherapeutic Agents in vitro and in vivo

C. Tse, H. Maecker, S. Rosenberg, 2011 .

The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo

C. Tse, H. Maecker, S. Rosenberg, 2011, Molecular Cancer Therapeutics.

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.

Brian J. Smith, C. Tse, A. Petros, 2014, ACS medicinal chemistry letters.

Clarithromycin therapy of experimental Treponema pallidum infections in hamsters

M. Mitten, N. Shipkowitz, J. Clement, 1993, Antimicrobial Agents and Chemotherapy.

Sialylation of Lipooligosaccharides Promotes Biofilm Formation by Nontypeable Haemophilus influenzae

M. L. Moore, M. Mitten, W. Swords, 2004, Infection and Immunity.

Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models

C. Tse, S. Fesik, S. Rosenberg, 2008, Clinical Cancer Research.

Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.

A. Vasudevan, Eric F. Johnson, V. Giranda, 2012, Bioorganic & medicinal chemistry letters.

Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens.

Suoming Zhang, S. Zhang, M. Mitten, 2001, Journal of medicinal chemistry.

Treatment of experimental Pneumocystis carinii infection by combination of clarithromycin and sulphamethoxazole.

M. Mitten, Y. Hui, N. Shipkowitz, 1994, Journal of Antimicrobial Chemotherapy.

A “Prozone-Like” Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor

Kedar S Vaidya, Mark G. Anderson, W. N. Pappano, 2017, Pharmacology.

ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo

C. Tse, S. Fesik, S. Chemburkar, 2008, Molecular Cancer Therapeutics.

The Volume of Three-Dimensional Cultures of Cancer Cells InVitro Influences Transcriptional Profile Differences and Similarities with Monolayer Cultures and Xenografted Tumors

Catarina Brito, Xin Lu, Kedar S Vaidya, 2017, Neoplasia.

Second-generation peptidomimetic inhibitors of protein farnesyltransferase demonstrating improved cellular potency and significant in vivo efficacy.

S. Ng, P. Kovar, S. Rosenberg, 1999, Journal of medicinal chemistry.

The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

Saul H. Rosenberg, Stephen W. Fesik, C. Tse, 2010, Cancer Chemotherapy and Pharmacology.

Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor

Xiaohong Song, Z. Tao, P. Kovar, 2020, ACS medicinal chemistry letters.

Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR

Kedar S Vaidya, A. Phillips, P. Ansell, 2021, Journal of Neuro-Oncology.

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

S. Fesik, Eric F. Johnson, S. Rosenberg, 2008, Cancer research.

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

M. Amiot, F. Peale, Leslie B. Lee, 2016, Molecular Cancer Therapeutics.

The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo

H. Maecker, S. Rosenberg, J. Leverson, 2011, Molecular Cancer Therapeutics.

ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo

S. Fesik, S. Chemburkar, S. Rosenberg, 2008, Molecular Cancer Therapeutics.

ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope

Kedar S Vaidya, A. Phillips, Dong Cheng, 2016, Molecular Cancer Therapeutics.

Practical Preclinical Model for Assessing the Potential for Unconjugated Hyperbilirubinemia Produced by Human Immunodeficiency Virus Protease Inhibitors

J. Waring, D. Kempf, J. Randolph, 2006, Antimicrobial Agents and Chemotherapy.